Saxagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the activity of endogenous incretin hormones, enhancing glucose-dependent insulin secretion in type 2 diabetes management. Simson Pharma's Saxagliptin reference standard and impurities support generic development and stability-indicating assay validation in this widely prescribed oral antidiabetic class.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Saxagliptin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.